. Increasing evidence showed that, IL-10, as an inhibitory cytokine, suppresses the differentiation and proliferation of Th17, inhibits the secretion of IFN-γ , and reduces the accumulation of NK cells 5 . In one of our early studies, we also found high percentage and density of CD19 + B cells in the tissues of invasive carcinoma of breast (IBCa) which expressed IL-10 in cytoplasm. We demonstrated that CD19 + B cells from IBCa patients but not that from healthy individuals could induce the expansion of Treg cells in vitro 12 . The immunosuppressive effects of Bregs have also been shown to be mediated via by promoting Tregs in mice models of autoimmune diseases 13 , and non-autoimmune diseases including cancers 14 . Nevertheless, the function and mechanism of Bregs in immune response remain poorly understood.
Regulatory B cells (Bregs), a subset of B cells, play a suppressive role in autoimmune diseases, inflammation, and anti-tumor immune response [1] [2] [3] [4] [5] . Based on the expression of various surface molecules, several populations of Bregs have been reported including B10 cells 6 , CD1d hi CD5 + CD19 + B cells 7 , CD19 + CD24 + CD38 + B cells 2 
or CD19
+ CD24 + CD27 + B cells 8 and so on. Recently, IL-10-producing was recognized as one of the most important characters of functional Bregs 6, [9] [10] [11] . Increasing evidence showed that, IL-10, as an inhibitory cytokine, suppresses the differentiation and proliferation of Th17, inhibits the secretion of IFN-γ , and reduces the accumulation of NK cells 5 . In one of our early studies, we also found high percentage and density of CD19 + B cells in the tissues of invasive carcinoma of breast (IBCa) which expressed IL-10 in cytoplasm. We demonstrated that CD19 + B cells from IBCa patients but not that from healthy individuals could induce the expansion of Treg cells in vitro 12 . The immunosuppressive effects of Bregs have also been shown to be mediated via by promoting Tregs in mice models of autoimmune diseases 13 , and non-autoimmune diseases including cancers 14 . Nevertheless, the function and mechanism of Bregs in immune response remain poorly understood.
Programmed death-ligand 1 (PD-L1), as a critical suppressive molecule, constitutively expresses on B lymphocytes, T lymphocytes, dendritic cells and monocytes [15] [16] [17] Fig. 1A,E) . However, The percentage of CD4 + CD25 + CD127 low/− T cells was significantly higher in the PBMCs of IBCa patients (6.06 ± 2.17%) compared with that in FIBma patients (2.91 ± 1.06%) and health individuals (2.28 ± 0.79%) (P < 0.05 for both; Fig. 1A,B) . Similarly, the ratio of CD4 + CD25 + CD127 low/− Tregs and CD4 + T cells was among the highest in IBCa patients in comparison with health individuals and FIBma patients (P < 0.05; Fig. 1F ).
Because PD-1 is an important molecule in immune suppression, we then evaluated the expression of PD-1 on CD4
+ T cells and its subsets including CD4
low/− Tregs in PBMCs. Based on the the expression level of PD-1, each cell population was divided into two distinct subpopulations, PD-1 lo and PD-1 hi (Fig. S1 ). Although the expression levels of PD-1 on CD4
low/− Tregs were significantly different between the PBMCs of FIBma (55.19 ± 9.98%) and healthy individuals (39.95 ± 16.10%)(P < 0.05; Fig. 1C,D) , no significant difference between IBCa patients (48.10 ± 18.60%) and healthy individuals (P > 0.05; Fig. 1C Fig. 2A) . However, the level of IL-10 secreting CD19 + B cells was higher in IBCa patients compared with that in FIBma patients (2.31 ± 1.01% vs 1.12 ± 0.41%; P = 0.046) (Fig. 2B) .
We (Fig. 2C,D) . Consistent with the findings of our previous study 12 , the level of IL-10 was significantly higher in the CD19 + CD24 + CD38 + B lymphocytes (39.18 ± 18.91%) than in the CD19 + CD24 − CD38 + B cells (20.72 ± 13.01%) and CD19 + CD24 + CD38 − B cells (20.48 ± 13.46%) (P = 0.023 and P = 0.0231, respectively) ( Fig. 2E ).
CD19
+ CD24 + CD38 + Bregs and its subsets were expanded in breast cancer patients.
Subsequently, we investigated the distribution of CD19 + CD24 + CD38 + Bregs and various subsets in the PBMCs of breast tumor patients. In comparison with FIBma patients and healthy participants (4.48 ± 1.91% and 4.49 ± 2.48%, respectively), the percentage of CD19
+ B cells was significantly higher in the PBMCs of IBCa patients with 10.99 ± 5.70% (P < 0.05) (Fig. 3A,B) .
Similar to the experiments in CD4 + T cells and Tregs, we determined the expression pattern of the negative immune regulator PD-L1 in B cells and CD19 + CD24 + CD38 + Bregs (Fig. 3C ). Significantly higher level of CD19 + CD24 + CD38 + PD-L1 + subset (83.74 ± 19.32%) was observed in the PBMCs of IBCa patients compared with that in FIBma patients (78.40 ± 13.96%) or healthy individuals (61.13 ± 20.51%) (P < 0.05, respectively) ( Fig. 3C,D) . In addition, both the PD-L1 lo and PD-L1 hi expression were found to be significantly higher on CD19 + CD24 + CD38 + Bregs (42.36 ± 23.27% and 14.02 ± 16.99%) compared with non-Bregs (24.58 ± 16.51% and 3.92 ± 8.18%; P < 0.001 for both) (Fig. 3E,F) .
We further investigated the relationships among the levels of CD19 + B cells, CD19 + CD24 + CD38 + Bregs, as well as CD19 + CD24 + CD38 + PD-L1 + Bregs in IBCa and the histopathological characteristics of IBCa, and found that the CD19 + B cells were significantly higher in patients with tumors more than 3cm (P = 0.019) and CD19
+ Bregs were among the highest patient at TNM stage T4 (P = 0.011) ( Table 2) .
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The relationship between CD4 + T cell subsets and CD19 + B cell subsets in IBCa. In our previous studies, we have shown that B cells from IBCa could induce Tregs in vitro 12 . In the present study, we further examined the correlation between CD4 + T cell subsets and CD19 
Discussion
Although the overall survival rate has been improved considerably over the past few decades with the advancement of treatment modalities, breast cancer is still the leading causes of cancer mortality in women 18 . The immunosuppression and immune escape are regarded as predicting factors for poor prognosis of solid cancers. Regulatory T cells (Tregs), defined as CD4
, mediate peripheral tolerance and prevent autoimmunity in healthy individuals. It has been recognized that Tregs serve as a key mediator that regulates and maintains the balance of immune response by suppressing the expansion of effector T cells 19 . Therefore, Tregs play a beneficial role in treatment of autoimmunity diseases. In contrast, there is usually an increased number of Tregs in the peripheral blood or tumor sites in patients who have cancer, including head and neck squamous cell carcinoma, breast cancer, lung cancer, colorectal cancer, pancreatic cancer, ovarian cancer and melanoma [20] [21] [22] . Numerous reports showed Tregs were associated with inhibition of immune response against cancer, tumor immune escape and metastasis 19 . Higher number of Tregs has been associated with higher risk of relapse and shorter relapse-free survival. A recent investigation suggested that Tregs may be an important pathological factor predicting a response to hormone therapy or chemotherapy in breast cancer patients and can be potential therapeutic target for breast cancer 23 . However, the mechanisms that regulate Tregs activity is only beginning to be elucidated.
We have shown in the present study and our previous report 12 15 . Meanwhile, PD-1 is also inducible on activated T-cell subsets 24 . The PD-1/PD-L1 interaction exerts inhibitory effects that limit effector cells response, prevent the triggering of immune-mediated tissue damage, and regulate the balance between T cell activation and tolerance 25 . A number of studies have indicated that PD-1/PD-L1 pathway is a crucial modulator of host immune responses in regulation of autoimmunity, tumor immunity, transplantation immunity, and allergy [26] [27] [28] . The majority of studies have focused on PD-L1 expressed on DCs or macrophages that suppress effector CD4 + T cells 26, 29 . In the present study, we analyzed the expression of PD-L1 on CD19 + CD24 + CD38 + Bregs in breast tumor patients with and healthy individuals. We confirmed that PD-L1 was higher on CD19 12 , led us to hypothesize that PD-L1 expressed on Bregs might inhibit the proliferation of PD-1 hi non-Tregs, and promote the expansion of Tregs to suppress immune response.
As negative function of B cells was demonstrated, B-cell depletion by anti-CD20 antibody was used to augment immunotherapy in multiple solid tumor models 31 . Further investigations confirmed that the absence of B lymphocytes reduced the number and function of Tregs and enhanced the anti-tumor response in a murine tumor model 31 . However, as important immune cells, depletion of B lymphocytes would lead to deficient adaptive immune responses. Furthermore, published studies have showed that the depletion of B lymphocytes by anti-CD20 antibody would enrich CD20 low/− Bregs and promote cancer escape 32 . So, Bregs maybe a useful target cells in tumor immunotherapy base on Breg-mediated immunosuppression. And the precise phenotype of Bregs need identified and further investigated in cancer. Here, we have shown the level of PD-L1 was higher on CD19 + CD24 + CD38 + Bregs in IBCa, and the percentage of PD-L1 + CD19 + CD24 + CD38 + Bregs was positively correlated with Tregs, but negatively correlated with PD-1 hi non-Tregs. These observations suggested that 
Materials and Methods
Reagents. The following monoclonal antibodies and reagents were used in this study: anti-human CD19-ECD (clone: J3-119) (Beckman Coulter Company, Marseille, France) and anti-human CD4-ECD (clone: SFCI12T411) were purchased from Beckman (USA); anti-human CD24-PE-cy7 (clone: eBioSN3), anti-human CD38-APC (clone: HIT2), and anti-human CD25-PE-cy7 (clone: BC96) were from eBiosciencs (San Jose, CA, USA); anti-human CD127-FITC (clone: A019D5) and anti-human PD-1-PE (clone: PD1.3. Lipopolysaccharide, PMA and calcium-ionomycin were obtained from Sigma (St Louis, USA). Peripheral immune cell isolation. Peripheral blood mononuclear cells (PBMCs) were isolated from blood sample via a ficoll density gradient (Amersham Biosciences, Sweden) centrifugation at 1800 rpm for 20 min at 4 °C. PBMCs were washed with FACS buffer and centrifuged at 1800 rpm for 5min prior to labeling with antibodies for flow cytometry analysis.
Patients and peripheral blood cells collection.
Surface staining and flow cytometry. Following isolation, the PBMCs were immediately labelled with the specific fluorochrome-conjugated antibodies including CD4-ECD, CD25-PE-cy7, CD127-FITC and PD-1-PE to identify the surface molecules of Tregs for 30 min at 4 °C. Labeled cells were re-suspended in 0.5 mL cell staining buffer, and analyzed using a flow cytometer (CytomicsTM FC500, Beckman Coulter, USA). The data was analyzed using FlowJo software (version 7.6.2, Ashland, OR, USA). Isotype controls were included for each staining. FMO controls were included for assessing background fluorescence. Meanwhile, CD4-FITC, CD4-PE, CD4-ECD and CD4-PE-cy7 were used for compensation. The compensation and FMO controls were performed as shown in Supplementary Figures 2 and 3 . The surface molecules of Breg were analyzed similarly. In brief, PBMCs were incubated with the specific fluorochrome-conjugated antibodies including CD19-ECD, CD38-APC, CD24-PE-cy7 and PD-L1-PE for 30 min at 4 °C. Labeled cells were re-suspended in 0.5 mL cell staining buffer, and analyzed using flow cytometer with FlowJo software (version 7.6.2, Ashland, OR, USA). Isotype controls were used for each staining, and FMO controls were included to assess background fluorescence. Meanwhile, CD4-PE, CD4-ECD, CD4-APC, and CD4-PE-cy7 were used for compensation.
Intracellular staining of IL-10 and flow cytometry analysis. Intracellular IL-10 staining and analysis by flow cytometry was performed as previously described 12 . Briefly, PBMCs cells were cultured in the RMPI 1640 media containing 10% fetal calf serum, 200 μ g/mL penicillin, 200 μ g/mL streptomycin and stimulated with LPS (1 μ g/mL) for 72 hour, then stimulated with PMA (50 ng/mL) and ionomycin (750 ng/mL) for 6 hour. Four hours prior to the termination, cells were blocked with GolgiStop (BD Biosciences, USA). Bregs were labeled as described above using CD19-ECD, CD24-Pecy7 and CD38-APC. For intracellular staining, cells were fixed with Fixation/Permeabilization solution and incubated with anti-human IL-10-FITC antibody for 30 min in the dark. Labeled cells were re-suspended in 0.5 mL cell staining buffer, and analyzed with flow cytometry. Isotype controls and FMO controls were included for all experiments. Meanwhile, CD4-FITC, CD4-PE, CD4-ECD, and CD4-APC, were used for compensation.
Statistical analysis. All of the data were presented as mean ± standard error of the mean and analyzed using ANOVA-test or Student t test. ANOVA-test and Student-Newman-Keuls (SNK) for post hoc test were used to compare the mean of the percentage of CD4 + T cells, CD19 + B cells and their subsets in patients, healthy individuals. Correlation was determined by the Pearson correlation. The P < 0.05 and P < 0.01 were considered as statistically significant and very significant, respectively. All analyses were done using SPSS 17.0 software (USA).
